OpenCGT平台填补了高端制剂与递送系统产业转化的关键空白。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息， 剂泰科技 日前 完成 4亿元人民币D轮融资 ， 由北京市医药健康产业投资基金 和大兴区产业投资基金联合领投。融资资金将加速剂泰科技多个战略重点的推进，包括平台自动化升 级、自研产品管线推进、深化国际战略合作及高端人才引进。 成立于 2020年的 剂泰科技 作为 一家人工智能（ AI）驱动纳米材料创新的生物科技公司，专注于 利用靶向药物递送和发现技术，帮助生命体战胜疾病和衰老，重获健康和活力 ，现已 成功自主开发 了 AI纳米基座大模型及三大核心解决方案：AiLNP（AI核酸递送系统设计平台）、AiRNA（AI mRNA序列设计平台）、AiTEM（AI小分子制剂设计平台）。 目前， 剂泰科技已具备实现肝脏、肺部、肌肉和免疫细胞等关键组织和细胞的脂质纳米颗粒（ LNP）精准靶向递送能力，在多器官、多组织靶向递送难题上取得突破性进展 ，为肿瘤、代谢系统 疾病、自体免疫性疾病、神经系统退行性疾病等提供成药机会，也在器官水平上为生命体抵抗衰老提 ...

Core Viewpoint - JiTai Technology, a leading AI-driven nanomedicine company, has completed a Series D financing round of 400 million RMB, aimed at accelerating its strategic initiatives in platform automation, product pipeline development, international collaboration, and talent acquisition [2][6]. Financing and Investment - The recent financing round was led by the Beijing Pharmaceutical and Health Industry Investment Fund and the Daxing District Industrial Investment Fund, contributing to a total funding exceeding 2 billion RMB (approximately 300 million USD) since the company's inception [2][6]. - JiTai Technology previously completed two financing rounds in February 2022, raising a total of 150 million USD, and a Series C round in June 2024, raising 100 million USD [5][6]. Company Overview - Founded in 2020, JiTai Technology focuses on AI-driven innovations in nanomaterials, specifically targeting drug delivery and discovery technologies to combat diseases and aging [3]. - The company was co-founded by prominent scientists, including Dr. Chen Hongmin and Dr. Lai Caida, and has developed three core AI platforms: AiLNP, AiRNA, and AiTEM [3]. Industry Position and Collaboration - JiTai Technology is recognized as one of the "Four Little Dragons" in AI pharmaceuticals, alongside Deep Intelligence, Crystal Technology, and InSilico Medicine, emphasizing a collaborative rather than competitive approach within the industry [4]. - The company has achieved breakthroughs in targeted delivery capabilities for key organs and cells, providing opportunities for treating various diseases, including tumors and neurodegenerative disorders [4]. Strategic Initiatives - The company has launched the Open CGT technology platform, which aims to address industry challenges in precise drug delivery and facilitate the development of breakthrough cell and gene therapies [6][7]. - The first project under this platform focuses on enabling Rui Zheng Gene to develop mRNA-LNP-based liver-targeted CRISPR gene editing therapies [7]. Future Outlook - JiTai Technology's CEO highlighted that cell and gene therapy (CGT) will be a pillar of China's biopharmaceutical industry, representing the next generation of drug development [8]. - The company aims to contribute significantly to the entire drug delivery process, facilitating the transition from early-stage pipelines to market-ready products [8].